News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe
Volume 23, Issue 12

News bites

EC probes J&J and Novartis

The European Commission has launched another antitrust investigation, this time examining whether contracts between Johnson & Johnson and Novartis were designed to delay the market entry of generic versions of Fentanyl in the Netherlands.

Read more at: http://www.PharmTech.com/ecprobe

GSK's US settlement

GlaxoSmithKline has come to a tentative agreement with the US government to conclude ongoing investigations relating to sales and marketing practices. The settlement is still subject to negotiation, but GSK expects to pay around $3 billion, which is covered by existing legal provisions.

Read more at: http://www.PharmTech.com/gsksettles

Lily–Amyline alliance ends

Eli Lilly and Amylin have terminated their alliance relating to the diabetes medication exenatide. Amylin will have responsibility for exanatide's global development and commercialisation while Eli Lilly will receive an upfront payment of $250 million and a secured note for $1.2 billion plus interest.

Read more at: http://www.PharmTech.com/lillyamylin

Annex 16 revisions

The EMA has released a concept paper for consultation that recommends a revision to Annex 16 of the Guide to Good Manufacturing of Medicinal Products. According to the EMA, the revision will address new falsified medicines legislation and the industry's complicated global supply chains.

Read more at: http://www.PharmTech.com/annex16


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here